CTDSP1 Human

CTD Small Phosphatase 1 Human Recombinant
Cat. No.
BT27194
Source
Escherichia Coli.
Synonyms
Carboxy-terminal domain RNA polymerase II polypeptide A small phosphatase 1, Nuclear LIM interactor-interacting factor 3, NLI-IF, NLI-interacting factor 3, Small C-terminal domain phosphatase 1, SCP1, Small CTD phosphatase 1, CTDSP1, NIF3, NLIIF.
Appearance
Sterile filtered colorless solution.
Purity
Greater than 90.0% as determined by SDS-PAGE.
Usage
THE BioTek's products are furnished for LABORATORY RESEARCH USE ONLY. They may not be used as drugs, agricultural or pesticidal products, food additives or household chemicals.
Shipped with Ice Packs
In Stock

Description

CTDSP1 produced in E.Coli is a single, non-glycosylated polypeptide chain containing 280 amino acids (1-260 a.a.) and having a molecular mass of 31.2kDa.
CTDSP1 is fused to a 20 amino acid His-tag at N-terminus & purified by proprietary chromatographic techniques.

Product Specs

Introduction
CTDSP1, a class 2C phosphatase, relies on its conserved DxD motif for activity. It exhibits a preference for dephosphorylating 'Ser-5' within the repeating heptad sequence found in the C-terminal domain (CTD) of RNA polymerase II's largest subunit, POLR2A. Furthermore, CTDSP1 exerts a negative regulatory effect on RNA polymerase II transcription, potentially by influencing the shift from initiation/capping to the processive elongation of transcripts.
Description
Produced in E. coli, CTDSP1 is a single, non-glycosylated polypeptide chain consisting of 280 amino acids (specifically, amino acids 1 through 260) and possessing a molecular mass of 31.2 kDa. This CTDSP1 variant is fused to a 20 amino acid His-tag at its N-terminus and undergoes purification using proprietary chromatographic techniques.
Physical Appearance
A clear and sterile solution.
Formulation
The provided solution contains CTDSP1 at a concentration of 1 mg/ml. It is formulated in a buffer consisting of 20 mM Tris-HCl (pH 8.0), 1 mM DTT, 20% glycerol, and 0.1 M NaCl.
Stability
For short-term storage (up to 2-4 weeks), the solution should be kept refrigerated at 4°C. For extended storage, it is recommended to freeze the solution at -20°C. To further enhance stability during long-term storage, the addition of a carrier protein like HSA or BSA (at a concentration of 0.1%) is advisable. Repeated freezing and thawing of the solution should be avoided.
Purity
Analysis by SDS-PAGE indicates a purity level exceeding 90.0%.
Synonyms
Carboxy-terminal domain RNA polymerase II polypeptide A small phosphatase 1, Nuclear LIM interactor-interacting factor 3, NLI-IF, NLI-interacting factor 3, Small C-terminal domain phosphatase 1, SCP1, Small CTD phosphatase 1, CTDSP1, NIF3, NLIIF.
Source
Escherichia Coli.
Amino Acid Sequence
MGSSHHHHHH SSGLVPRGSH MDSSAVITQI SKEEARGPLR GKGDQKSAAS QKPRSRGILH SLFCCVCRDD GEALPAHSGA PLLVEENGAI PKTPVQYLLP EAKAQDSDKI CVVIDLDETL VHSSFKPVNN ADFIIPVEID GVVHQVYVLK RPHVDEFLQR MGELFECVLF TASLAKYADP VADLLDKWGA FRARLFRESC VFHRGNYVKD LSRLGRDLRR VLILDNSPAS YVFHPDNAVP VASWFDNMSD TELHDLLPFF EQLSRVDDVY SVLRQPRPGS.

Product Science Overview

Structure and Function

CTDSP1 is characterized by a conserved catalytic site with the motif DXDXT/V, which is essential for its phosphatase activity . The enzyme preferentially catalyzes the dephosphorylation of the serine residue at position 5 (Ser5) within the heptapeptide repeats of the RNA polymerase II CTD . This dephosphorylation is a critical step in the regulation of gene expression, as it influences the transition between different phases of the transcription cycle.

Biological Significance

CTDSP1 is involved in several pivotal biological processes:

  1. Transcriptional Regulation: By dephosphorylating Ser5, CTDSP1 regulates the activity of RNA polymerase II, thereby influencing the transcription of various genes .
  2. Neuronal Gene Silencing: CTDSP1 is a component of the repressor element 1 (RE-1)-silencing transcription factor (REST) complex, which silences neuronal genes in non-neuronal cells .
  3. Cell Cycle Regulation: It plays a role in the G1/S phase transition of the cell cycle .
  4. Osteoblast Differentiation: CTDSP1 is implicated in the differentiation of osteoblasts, which are cells responsible for bone formation .
Clinical Implications

Recent studies have highlighted the potential of CTDSP1 as a therapeutic target. Negative regulation of CTDSP1 has been shown to suppress cancer invasion in neuroglioma cells . This makes CTDSP1 a promising target for drug development aimed at treating certain types of cancer.

Recombinant Production

Human recombinant CTDSP1 is produced in Escherichia coli (E. coli) as a single, non-glycosylated polypeptide chain containing 280 amino acids, with a molecular mass of approximately 31.2 kDa . The recombinant protein is often fused to a His-tag at the N-terminus to facilitate purification through chromatographic techniques .

Quick Inquiry

Personal Email Detected
Please use an institutional or corporate email address for inquiries. Personal email accounts ( such as Gmail, Yahoo, and Outlook) are not accepted. *
© Copyright 2024 Thebiotek. All Rights Reserved.